Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ESPR Esperion Therapeutics

Trading 03-05 09:55:20 EST

2.92

+0.01

+0.34%

High2.93	Low2.81	Vol330.91K
Open2.85	D1 Closing2.91	Amplitude3.95%
Mkt Cap698.07M	Tradable Cap692.04M	Total Shares239.06M
T/O946.90K	T/O Rate0.14%	Tradable Shares237.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"ESPR","market":"US","secType":"STK","nameCN":"Esperion Therapeutics","latestPrice":2.92,"timestamp":1772722512957,"preClose":2.91,"halted":0,"volume":330914,"delay":0,"changeRate":0.0034364261168384146,"floatShares":237000000,"shares":239063437,"eps":-0.535792,"marketStatus":"Trading","change":0.01,"latestTime":"03-05 09:55:20 EST","open":2.85,"high":2.925,"low":2.81,"amount":946898.8951928,"amplitude":0.039519,"askPrice":2.93,"askSize":400,"bidPrice":2.92,"bidSize":112,"shortable":3,"etf":0,"ttmEps":-0.535792,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772744400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1372219200000,"exchange":"NASDAQ","adjPreClose":2.91,"preHourTrading":{"tag":"盘前","latestPrice":2.85,"preClose":2.91,"latestTime":"09:29 EST","volume":9092,"amount":26417.9134056,"timestamp":1772720999962,"change":-0.06,"changeRate":-0.020619,"amplitude":0.034364},"postHourTrading":{"tag":"盘后","latestPrice":2.91,"preClose":2.91,"latestTime":"19:54 EST","volume":15953,"amount":46478.8299,"timestamp":1772672058798,"change":0,"changeRate":0,"amplitude":0.017216},"volumeRatio":1.268777,"impliedVol":0.8164,"impliedVolPercentile":0.5339},"requestUrl":"/m/hq/s/ESPR","defaultTab":"news","newsList":[{"id":"2617541909","title":"HLS Therapeutics Announces Nilemdotm (Bempedoic Acid) Is NOW Available in Canada for the Reduction of Ldl-Cholesterol in Patients at Risk of Cardiovascular Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2617541909","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617541909?lang=en_us&edition=fundamental","pubTime":"2026-03-05 20:03","pubTimestamp":1772712199,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260305:nFWN3ZT0I4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2616653650","title":"Analysts Conflicted on These Healthcare Names: Xenon (XENE), Arvinas Holding Company (ARVN) and Esperion (ESPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616653650","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616653650?lang=en_us&edition=fundamental","pubTime":"2026-03-04 17:50","pubTimestamp":1772617813,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xenon (XENE – Research Report), Arvinas Holding Co...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-xenon-xene-arvinas-holding-company-arvn-and-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-healthcare-names-xenon-xene-arvinas-holding-company-arvn-and-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4137","ARVN","LABU","LU0128526141.USD","BK4588","BK4581","XLV","XENE","LU0029874061.USD","ESPR","BK4007","XBI","HCSG","BK4139"],"gpt_icon":0},{"id":"2616730263","title":"Sector Update: Health Care Stocks Decline Tuesday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2616730263","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616730263?lang=en_us&edition=fundamental","pubTime":"2026-03-04 02:55","pubTimestamp":1772564106,"startTime":"0","endTime":"0","summary":"Health care stocks retreated Tuesday afternoon, with the NYSE Health Care Index falling 1.2% and the State Street Health Care Select Sector SPDR ETF  shedding 1%.The iShares Biotechnology ETF  dropped 1.4%.In corporate news, Cigna  said David M. Cordani will retire as chief executive on July 1. The company's board has appointed Chief Operating Officer Brian Evanko as the next CEO. Shares fell 2.8%.Medline  said Blackstone , Carlyle , Hellman & Friedman, and a subsidiary of the Abu Dhabi Investment Authority have started an underwritten public offering of 75 million shares of its class A common stock. Medline shares were down 2.5%.Esperion Therapeutics  shares fell past 7% after the company said Tuesday it agreed to buy privately held Corstasis Therapeutics for $75 million in upfront cash.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","BX","IE00BN8TJ469.HKD","BK4198","CI","IE0002270589.USD","BK4581","IBB","IE00BLSP4452.SGD","XBI","LU0868494617.USD","LU1059921491.USD","ESPR","IE00B3QW5Z07.USD","MDLN","BK4007","CG","LU0289739699.SGD","LU1261432733.SGD","IE00BGHQF748.EUR","IE0004445239.USD","BK4585","BK4135","BK4196","IE00B19Z3581.USD","LU0058720904.USD","IE00BBT3K403.USD","IE00B64PRP62.GBP","IE00BLSP4239.USD","BK4588","IE00B19Z3B42.SGD","IE00BSNM7G36.USD","LABU"],"gpt_icon":0},{"id":"2616373423","title":"Esperion Therapeutics Is Maintained at Buy by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2616373423","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616373423?lang=en_us&edition=fundamental","pubTime":"2026-03-04 02:42","pubTimestamp":1772563320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ESPR/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 03, 2026 13:42 ET (18:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR"],"gpt_icon":0},{"id":"2616321535","title":"Analysts Are Bullish on Top Healthcare Stocks: Pulmonx (LUNG), Esperion (ESPR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616321535","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616321535?lang=en_us&edition=fundamental","pubTime":"2026-03-03 22:50","pubTimestamp":1772549413,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Pulmonx (LUNG – Research Report), Esperion (ESPR – R...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pulmonx-lung-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-pulmonx-lung-esperion-espr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","LUNG","BK4112","LU0029874061.USD","BK4007","BK4585","LU0128526141.USD","XBI","BK4588","BLSX","BK4581","BK4198","BLSG","LABU","BK4082","BK4137"],"gpt_icon":0},{"id":"2616349623","title":"Esperion Therapeutics to acquire Corstasis Therapeutics for $75 million upfront","url":"https://stock-news.laohu8.com/highlight/detail?id=2616349623","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616349623?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:00","pubTimestamp":1772535628,"startTime":"0","endTime":"0","summary":"Esperion entered a definitive agreement to acquire privately held Corstasis Therapeutics, adding Corstasis’s Enbumyst , an FDA-approved intranasal loop diuretic for edema associated with congestive heart failure and hepatic and renal disease. Under the deal terms, Esperion will pay $75 million upfront in cash, with up to $180 million in potential commercial and regulatory milestone payments and low double-digit royalties on worldwide Enbumyst sales and follow-on products. Esperion expects the transaction to close in the second quarter of 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL39btGJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","LU0314104364.USD","LU2210150020.SGD","SG9999014039.USD","BK4112","IE00B3QW5Z07.USD","LU2210149790.SGD","SG9999014021.USD","BK4007","NDAQ","BK4588","ESPR","SG9999014005.SGD","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2616496533","title":"Esperion Therapeutics Inc - to Finance Acquisition Through Credit Facilities","url":"https://stock-news.laohu8.com/highlight/detail?id=2616496533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616496533?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:00","pubTimestamp":1772535601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA6PPDWP:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ESPR","BK4007"],"gpt_icon":0},{"id":"2616349661","title":"Esperion Therapeutics Inc - Deal Includes $75 Mln Cash Payment and $180 Mln Milestone Payments","url":"https://stock-news.laohu8.com/highlight/detail?id=2616349661","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616349661?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:00","pubTimestamp":1772535601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA6PPDWP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2616634966","title":"Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise With Enbumyst™ (Bumetanide Nasal Spray)","url":"https://stock-news.laohu8.com/highlight/detail?id=2616634966","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616634966?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:00","pubTimestamp":1772535601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA5QYCKC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2616349662","title":"Esperion Therapeutics Inc - Corstasis Shareholders Eligible for up to $180 Mln in Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2616349662","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616349662?lang=en_us&edition=fundamental","pubTime":"2026-03-03 19:00","pubTimestamp":1772535601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nTUA5QYCKC:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2613284711","title":"Esperion Therapeutics Inc. Schedules Quarterly and Full-Year Financial Results Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2613284711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613284711?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:03","pubTimestamp":1771938198,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. will report fourth quarter and full year 2025 financial results before the market opens on March 10, 2026, and management will host a webcast at 8:00 a.m. ET the same day to discuss the results and provide business updates. The live audio webcast will be available in the investor and media section of the Esperion website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL1jrvFv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","ESPR","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","SG9999014021.USD","IE00BKPKM429.USD","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","LU2210149790.SGD","NDAQ","BK4112","BK4585","SG9999014039.USD","LU2210150020.SGD","BK4007","SG9999014013.SGD","LU0314104364.USD"],"gpt_icon":0},{"id":"2613790840","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2613790840","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613790840?lang=en_us&edition=fundamental","pubTime":"2026-02-24 19:00","pubTimestamp":1771930800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Albany Intl Corp. Class A                        4Q       .61        BMO. Bank of Nova Scotia                              1Q      1.43    6:15 AM. Bowhead Specialty Hldgs Inc.                     4Q       .44    7:00 AM. Clean Energy Fuels Corp.                        4Q      (.05)   4:05 PM. Controladora Vuela Comp de Aviacion             4Q       .20        AMC","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDNA","AXGN","BBIO","DRS","ACHC","ADTN","BNS","CSGP","DDS","ACAD","CORT","CCC","EOG","AMT","ECG","CECO","CGBD","EXPD","ATRO","AS","BRSL","CLNE","ESPR","DAWN","ESTA","AII","BOW","CAVA","ARVN","EVH","AXON","ASR","CBLL","DOCN","ABCL","ATEC","CWH","CYTK","AIN","FERG","HSBC","ELAN","AWI","AHCO","APLS","CIFR","EXLS","CLVT","BXC"],"gpt_icon":1},{"id":"2612445152","title":"Esperion to Participate in 2026 Citizens Life Sciences Conference Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2612445152","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612445152?lang=en_us&edition=fundamental","pubTime":"2026-02-18 21:02","pubTimestamp":1771419753,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 18, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260218:nNDL6gFQzL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","ESPR","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","NDAQ","LU0314104364.USD","SG9999014039.USD","BK4588","IE00B3QW5Z07.USD","LU2210150020.SGD","SG9999014005.SGD","BK4585","BK4007","BK4112"],"gpt_icon":0},{"id":"2612842466","title":"Esperion Therapeutics: Strengthened Bempedoic Acid Patent Protection and Growing Cardiovascular Franchise Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2612842466","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612842466?lang=en_us&edition=fundamental","pubTime":"2026-02-18 00:15","pubTimestamp":1771344928,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Esperion today and set a price target of $16.00. Joseph Pantginis has given his...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/esperion-therapeutics-strengthened-bempedoic-acid-patent-protection-and-growing-cardiovascular-franchise-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/esperion-therapeutics-strengthened-bempedoic-acid-patent-protection-and-growing-cardiovascular-franchise-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ESPR","CSII"],"gpt_icon":0},{"id":"2612457879","title":"Esperion reaches settlement agreement with Alkem","url":"https://stock-news.laohu8.com/highlight/detail?id=2612457879","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612457879?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:16","pubTimestamp":1771334188,"startTime":"0","endTime":"0","summary":"Esperion (ESPR) entered into a settlement agreement with Alkem Laboratories. This agreement resolves the patent litigation brought by Esperion agai...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/esperion-reaches-settlement-agreement-with-alkem-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/esperion-reaches-settlement-agreement-with-alkem-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2612452517","title":"Esperion Faces Ongoing Patent Litigation Over NEXLETOL and NEXLIZET Generics","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452517","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452517?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333248,"startTime":"0","endTime":"0","summary":"Esperion Therapeutics Inc. has ongoing patent litigation against several companies, including Aurobindo Pharma, MSN Pharmaceuticals, Renata Limited, and Sandoz, regarding generic versions of its cholesterol-lowering drugs, NEXLETOL and NEXLIZET. The company recently reached a settlement with Alkem Laboratories, under which Alkem agreed not to market generic versions of these drugs in the United States before April 19, 2040, unless certain conditions apply. Litigation with the remaining defendants continues.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Esperion Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 17, 2026, and is solely responsible for the information contain","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL2B1N9w:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","ESPR","LU2095319765.USD","NDAQ","BK4007","SG9999014021.USD","SG9999014039.USD","LU2210149790.SGD","SG9999014013.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2612529634","title":"Esperion Therapeutics: Agreement Resolves Patent Litigation Brought by Esperion in Response to Alkem's Andas for Generic Nexletol, Nexlizet","url":"https://stock-news.laohu8.com/highlight/detail?id=2612529634","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612529634?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333212,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA4YTVND:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2612452653","title":"Esperion Therapeutics Inc - Alkem Agrees Not to Market Generic Nexletol or Nexlizet in US Before April 19, 2040","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452653","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452653?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333212,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA4YTVND:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2612452557","title":"Esperion Reaches Settlement Agreement With Fifth Anda Filer Not to Market Generic Version of Nexletol® (Bempedoic Acid) & Nexlizet® (Bempedoic Acid & Ezetimibe) Prior to April 19, 2040","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452557","media":"THOMSON REUTERS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452557?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333212,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nTUA4YTVND:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ESPR"],"gpt_icon":0},{"id":"2612945766","title":"Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040","url":"https://stock-news.laohu8.com/highlight/detail?id=2612945766","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612945766?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:00","pubTimestamp":1771333200,"startTime":"0","endTime":"0","summary":"ANN ARBOR, Mich., Feb.  17, 2026  (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Alkem Laboratories Ltd. (Alkem). This agreement resol","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/17/3239166/0/en/Esperion-Reaches-Settlement-Agreement-with-Fifth-ANDA-Filer-Not-to-Market-Generic-Version-of-NEXLETOL-bempedoic-acid-NEXLIZET-bempedoic-acid-ezetimibe-Prior-to-April-19-2040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESPR","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.esperion.com","stockEarnings":[{"period":"1week","weight":-0.1261},{"period":"1month","weight":-0.1686},{"period":"3month","weight":-0.2322},{"period":"6month","weight":0.0858},{"period":"1year","weight":0.6441},{"period":"ytd","weight":-0.2135}],"compareEarnings":[{"period":"1week","weight":-0.0116},{"period":"1month","weight":-0.0148},{"period":"3month","weight":0.0011},{"period":"6month","weight":0.0585},{"period":"1year","weight":0.1877},{"period":"ytd","weight":0.0047}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.","yearOnYearQuotes":[{"month":1,"riseRate":0.461538,"avgChangeRate":-0.043403},{"month":2,"riseRate":0.461538,"avgChangeRate":0.113863},{"month":3,"riseRate":0.461538,"avgChangeRate":-0.035825},{"month":4,"riseRate":0.416667,"avgChangeRate":-0.028114},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.032489},{"month":6,"riseRate":0.75,"avgChangeRate":0.035061},{"month":7,"riseRate":0.461538,"avgChangeRate":-0.001019},{"month":8,"riseRate":0.461538,"avgChangeRate":0.026549},{"month":9,"riseRate":0.538462,"avgChangeRate":-0.000828},{"month":10,"riseRate":0.538462,"avgChangeRate":-0.017419},{"month":11,"riseRate":0.692308,"avgChangeRate":0.148542},{"month":12,"riseRate":0.461538,"avgChangeRate":0.067177}],"exchange":"NASDAQ","name":"Esperion Therapeutics","nameEN":"Esperion Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Esperion Therapeutics,ESPR,Esperion Therapeutics股票,Esperion Therapeutics股票老虎,Esperion Therapeutics股票老虎国际,Esperion Therapeutics行情,Esperion Therapeutics股票行情,Esperion Therapeutics股价,Esperion Therapeutics股市,Esperion Therapeutics股票价格,Esperion Therapeutics股票交易,Esperion Therapeutics股票购买,Esperion Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Esperion Therapeutics(ESPR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Esperion Therapeutics(ESPR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}